They reported that patients with TP53 mutations had lower survival compared with those without TP53 mutations in colon, lung and pancreas adenocarcinoma, acute myeloid leukaemia and other epithelial cancers. The gene discussed is TP53; the disease is pancreatic adenocarcinoma.